drugset / Trial / NCT01013064
A Study of HM10760A (Long-acting Erythropoietin (EPO)) in Healthy Korean Subjects
RandomizedSingle-groupTriple-blindTreatment
Summary
Study design: * Randomized, double-blind, placebo-controlled, sequential dose escalation * Six ascending dose cohorts are planned Primary Objective: * To evaluate the safety profile of single escalating intravenous dose levels of HM10760A
Timeline
- Start
- 2009-11
- Primary completion
- 2010-12
- Completion
- 2011-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HM10760A | Protein / enzyme biologic | 0.04 ug/kg | Intravenous |
| Subject | HM10760A | Protein / enzyme biologic | 2 ug/kg | Intravenous |
Indications
No indication recorded.